Osteoarthritis is a multifactorial joint disease affecting millions of patients all around the world. Some inflammatory
mediators as interleukin-1 beta and tumor necrosis factor-alpha, among others, are involved in stimulating the
metalloproteinases production in the osteoarthritis disease process. These enzymes degrade all the articular cartilage
extracellular matrix components; such as collagen, aggrecan and non-collagen proteins. In osteoarthritis, the expression of
metalloproteinases is elevated and some considerable efforts have been made in order to design effective inhibitors of
enzymes activity and/or synthesis with the intention of limiting the connective tissues destruction within the joints. As
of yet, there are no effective clinical inhibitors; however, published patents employing metalloproteinases as early
osteoarthritis biomarkers and/or targets for effective therapies might be able to provide new opportunities to prevent joint
destruction related to osteoarthritis.
Keywords: Aggrecan, biomarkers, cartilage, collagen, metalloproteinases, osteoarthritis, patents.
Rights & PermissionsPrintExport